INSIGHTEC’s Focused Ultrasound Earns Positive NICE Guidance for Treatment of Essential Tremor
Posted in Industry News on 2nd Jul 2018
Unilateral MRI-guided Focused Ultrasound Thalamotomy for Treatment-resistant Essential Tremor Recognised by National Institute for Health and Care Excellence
INSIGHTEC®, a global medical technology innovator of incisionless surgery, has announced that The National Institute for Health and Care Excellence (NICE) issued a positive NICE guidance for unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor (ET). ET affects more than one million people in the UK and impacts their ability to perform everyday tasks due to uncontrollable shaking of their hands.
The Imperial College Healthcare NHS Trust is the first and only site in the UK with the Exablate Neuro™ technology to treat essential tremor. To date 16 patients with ET have been treated at St. Mary’s by an expert, multidisciplinary team including Professor Wladyslaw Gedroyc, Consultant Radiologist, Dr. Peter Bain, Consultant Neurologist and Professor Dipankar Nandi, Consultant Neurosurgeon.
Essential tremor patients treated at St Mary’s have experienced very substantial improvement in the severity of their tremor as well as their quality of life. In addition, the safety profile is favourable with minor, often temporary side effects experienced by this group.
Professor Dipankar Nandi, Consultant Neurosurgeon and Head of Department, St Mary’s Hospital, Imperial College Healthcare NHS Trust.
During the treatment, ultrasound waves pass safely through the skull to ablate a tiny spot in the brain considered to be responsible for the tremor. The result is often an immediate improvement of the tremor in the treated hand. Due to the incisionless nature of focused ultrasound, there is no risk of infection and patients recover quickly.
The positive NICE guidance adds to the growing body of positive health technology determinations for incisionless brain surgery using INSIGHTEC’s Exablate Neuro. This is a critical step toward increased patient access to our technology around the globe.
Maurice R. Ferré, MD, Chief Executive Officer and Chairman of the Board of INSIGHTEC
For more information on the NICE guidance, please visit NICE.org.uk.
INSIGHTEC is a global medical technology innovator transforming patient lives through incisionless brain surgery using MR-guided focused ultrasound. The company’s award-winning Exablate Neuro™ is used by neurosurgeons to perform the Neuravive™ treatment to deliver immediate and durable tremor relief for essential tremor patients. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. INSIGHTEC is headquartered in Haifa, Israel, and Miami, Florida, with offices in Dallas, Tokyo and Shanghai.
For more information, please visit: http://www.insightec.com/